Skip to main content
Julie Park, MD, Pediatric Hematology & Oncology, Memphis, TN

Julie Ruggieri Park MD (She/Her)


Full Member, and Chair Department of Oncology St. Jude Children's Research Hospital

Join to View Full Profile
  • 260 Danny Thomas PlaceMemphis, TN 38105

  • Phone+1 901-595-4329

Dr. Park is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Washington
    University of WashingtonFellowship, Pediatric Hematology/Oncology, 1991 - 1994
  • University of Washington
    University of WashingtonResidency, Pediatrics, 1988 - 1991
  • University of Vermont College of Medicine
    University of Vermont College of MedicineClass of 1988

Certifications & Licensure

  • TN State Medical License
    TN State Medical License 2023 - 2025
  • WA State Medical License
    WA State Medical License 1988 - 2023
  • Pediatric Hematology-Oncology
    American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2011-2014
  • America's Top Doctors for Cancer Castle Connolly, 2011-2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo
    Julie R. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses
    Julie R. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • FDA Committee Unanimously Rejects 131-I-Omburtamab for Neuroblastoma
    FDA Committee Unanimously Rejects 131-I-Omburtamab for NeuroblastomaOctober 28th, 2022
  • Practice-Changing Trial in Neuroblastoma, but Questions Remain
    Practice-Changing Trial in Neuroblastoma, but Questions RemainAugust 27th, 2019
  • 74 Oncologists on the Move
    74 Oncologists on the MoveOctober 11th, 2023

Grant Support

  • COG Advl0419: Valproic Acid In Children With Recurrent/Progressive Solid TumorsNational Center For Research Resources2007
  • COG Advl0416: A Phase 1 Study Of SAHA In Pediatric Patients With RecurrentNational Center For Research Resources2007
  • COG Advl0413: A Phase I Study Of The RAF Kinase And Receptor Tyrosine KinaseNational Center For Research Resources2007
  • NANT 2004-01: A Phase I Study Of Zoledronic Acid (ZOMETA) With CyclophosphamideNational Center For Research Resources2006–2007
  • NANT 2003-01: A Phase I Study Of Oral Irinotecan, Temozolomide, And CefiximeNational Center For Research Resources2006–2007
  • Advl0319 Phase I Study Of CC-5013 (LENALIDOMIDE) In Pediatric PatientsNational Center For Research Resources2006–2007
  • NANT 2001-03: Phase 1 Study Of CEP-701 In Patients With Refractory NeuroblastomaNational Center For Research Resources2004–2007
  • COG Advl0416: A Study Of SAHA In Pediatric Patients Wth Recurrent Solid TumorsNational Center For Research Resources2006
  • COG Advl0317: A Phase I Study Of PS-341 (Velcade, Bortezomiv) In Ped PatientsNational Center For Research Resources2006
  • COG Advl0316: A Phase I Study Of 17-AAG In Relapsed/Refractory PediatricNational Center For Research Resources2006
  • COG Advl0214: A Phase I Study Of Single Agent OSI-774 (TARCEVA)National Center For Research Resources2006
  • COG Advl0314: A Phase 1 Study Of Bevacizumab In Refractory Solid TumorsNational Center For Research Resources2005–2006
  • NANT 2002-01 Phase 1 Study Of High Dose Pyrasolacridine (Pza)(Nsc 366140) SupporNational Center For Research Resources2004–2006
  • Novel Therapies For High-Risk NeuroblastomaNational Cancer Institute2002–2006
  • Cog-Anbl02p1: A Pilot Induction Regimen Incorporating Topotecan For Treatment ONational Center For Research Resources2005
  • Cog-Advl0311: Pemetrexed In Children And Adolescents With Recurrent Solid TumorsNational Center For Research Resources2005
  • COG Advl0316: 17-AAG In Pediatric Patients With Solid Tumors Or LeukemiaNational Center For Research Resources2005
  • COG Advl0215: Decitabine In Combination With Doxorubicin And CyclophosphamideNational Center For Research Resources2005
  • COG Advl0211: G3139 With Cytotoxic Chemotherapy In Relapsed Childhood TumorsNational Center For Research Resources2005
  • Cog-Anbl0321: A Phase II Study Of Fenretinide (Nsc #374551, IND #40294) In ChiaNational Center For Research Resources2004
  • COG Advl0215: A Phase I Study Of Decitabine (Nsc #127716, IND #50733) In CombinNational Center For Research Resources2004
  • COG Advl0212 - A Phase I Study Of Depsipeptide (Nsc # 630176, IND # 51810) In PSNational Center For Research Resources2004
  • COG Advl0211 - A Phase I Trial Of G3139 (Bcl-2 Antisense, NSC# 683428, Ind# 588sNational Center For Research Resources2004
  • Ccg-A0981, A Phase I Intergroup Trial Of The Hu14.18-Il2 Fusion Protein In ChilsNational Center For Research Resources2004

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: